Table 2.
Demographics and baseline characteristics of patients who developed serious adverse drug reactions (n = 13)
| Characteristic | Value |
|---|---|
| Mean age, years (range) | 57.5 (24–85) |
| Male, n (%) | 9 (69) |
| ECOG performance status, n (%) | |
| 0 | 7 (54) |
| 1 | 6 (46) |
| 2 | 0 |
| Metastatic melanoma stage, n (%) | |
| IIIc | 1 (8) |
| IV | 1 (8) |
| IV (M1b) | 2 (15) |
| IV (M1c) | 9 (69) |
| Treatment line, n (%) | |
| First | 1 (8) |
| Second | 3 (23) |
| Third | 6 (46) |
| Fourth | 2 (15) |
| Unknown | 1 (8) |
| Prior therapy, n (%) | |
| Interferon beta | 1 (8) |
| Nivolumab | 9 (69) |
| Dabrafenib | 1 (8) |
| Pembrolizumab | 1 (8) |
| Unknown | 1 (8) |
| None | 1 (8) |